These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33870432)

  • 41. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating PD-1
    Zhang L; Li H; Ren H; Hu P
    Mol Immunol; 2018 Nov; 103():270-278. PubMed ID: 30340072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
    Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
    Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
    Hagiwara S; Nishida N; Watanabe T; Ida H; Sakurai T; Ueshima K; Takita M; Komeda Y; Nishijima N; Osaki Y; Kudo M
    Antivir Ther; 2018; 23(6):513-521. PubMed ID: 29438098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro.
    Chen M; Hu P; Ling N; Peng H; Lei Y; Hu H; Zhang D; Ren H
    PLoS One; 2015; 10(3):e0120086. PubMed ID: 25774808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of T regulatory cells with natural course and response to treatment with interferon-α in patients with chronic hepatitis B infection.
    Xu HT; Xing TJ; Li H; Ye J
    Chin Med J (Engl); 2012 Apr; 125(8):1465-8. PubMed ID: 22613654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.
    Yeh ML; Huang JF; Yu ML; Chuang WL
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):427-435. PubMed ID: 33338385
    [No Abstract]   [Full Text] [Related]  

  • 52. Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients.
    Ning L; Huang X; Xu Y; Yang G; Yang J; Fu Q; Zhang Q; Liu H; Wu X; Wang Z; Luo K
    J Interferon Cytokine Res; 2019 Dec; 39(12):740-751. PubMed ID: 31329012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
    Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.
    Wijaya RS; Read SA; Schibeci S; Eslam M; Azardaryany MK; El-Khobar K; van der Poorten D; Lin R; Yuen L; Lam V; George J; Douglas MW; Ahlenstiel G
    J Hepatol; 2019 Aug; 71(2):252-264. PubMed ID: 30905683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.
    Peng H; Wei F; Liu JY; Hu HD; Ren H; Hu P
    Hepatol Int; 2015 Oct; 9(4):543-57. PubMed ID: 26162453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.
    Fletcher SP; Chin DJ; Gruenbaum L; Bitter H; Rasmussen E; Ravindran P; Swinney DC; Birzele F; Schmucki R; Lorenz SH; Kopetzki E; Carter J; Triyatni M; Thampi LM; Yang J; AlDeghaither D; Murreddu MG; Cote P; Menne S
    PLoS Pathog; 2015 Sep; 11(9):e1005103. PubMed ID: 26352406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection.
    Tjwa ET; van Oord GW; Biesta PJ; Boonstra A; Janssen HL; Woltman AM
    J Virol; 2012 Apr; 86(8):4102-9. PubMed ID: 22318141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
    Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.